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Background: To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months
post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs
(DMARDs) in early RA, which is an unmet need in developing countries.
Patients and methods: A cohort of 140 predominantly (88.5 %) black female South African patients with early
RA was treated with synthetic DMARDs, mostly methotrexate (MTX) alone, or in combination with low-dose oral
corticosteroids (CS). Circulating ACPA and a panel of circulating cytokines/chemokines/growth factors were
measured at baseline and after 6 months of therapy in relation to disease activity and Shared Epitope (SE).
Results: Following 6 months of therapy, the median simplified disease activity index (SDAI) declined from a
baseline of 41.4 to 16.0 (p = 0.0001) for the entire cohort, which was paralleled by significant falls in median serum
ACPA levels (516.6 vs. 255.7 units/ml, p = <0.0001) and several of the circulating cytokines (IL-4, IL-7, IL-8, G-CSF,
VEGF; p < 0.0010 – p < 0.0001) which were most evident in the subgroup of patients treated with a combination
of MTX and CS. Although biomarker concentrations decreased most notably in the low-disease activity group
post-therapy, no significant correlations between these biomarkers and disease activity were observed, Baseline
ACPA levels, but not SDAI or cytokines, were significantly higher in the subgroup of risk allele-positive patients
(561.1 vs. 331.9 units/ml, p < 0.05), while no associations with ACPA and a smoking history were evident.
Conclusions: The use of DMARDs in RA is associated with significant decreases in ACPA and cytokines which did
not correlate with changes in SDAI, precluding the utility of serial measurement of these biomarkers to monitor
early responses to therapy, but may have prognostic value.
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Raised levels of anti-citrullinated peptide antibodies (ACPA)
levels have diagnostic and prognostic value, and have been
incorporated in the 2010 Eular/ACR rheumatoid arthritis
(RA) classification criteria [1]. Studies investigating
therapy-associated alterations in ACPA levels in patients
with early RA have focused predominantly on biologic
disease-modifying anti-rheumatic drugs (DMARDs) [2].
However, the association of a decrease in ACPA levels with
therapeutic response has been variable [3–13]. On the other
hand, raised ACPA levels may account for relapse and per-
sistence of disease, with the magnitude of the pre-therapy
levels being inversely associated with response to metho-
trexate (MTX) in early undifferentiated arthritis [14]. ACPA
levels have not only been shown to correlate with response
to anti-TNF therapy, but are also predictive of response to
rituximab [15].
Cytokines play an integral role in the pathogenesis of
RA and their importance as therapeutic targets is well
established. However, the utility of serial measurement
of circulating cytokines in RA is not clearly defined.
Changes in cytokine levels post-therapy, especially the
balance between pro- and anti-inflammatory cytokines,
have the potential to aid in monitoring treatment
response, guide future therapy and/or have prognostic
implications [16]. For example, a decrease in IL-7 levels
after treatment with MTX has been found to correlate
with improved clinical measures of disease activity [17].
In addition, TNF levels below 20.1 pg/ml have been
shown to be associated with a good response to MTX,
while a low IL-2 level at baseline is an independent pre-
dictor of response to synthetic DMARDs [18]. IL-6 levels
greater than 4.03 pg/ml post-treatment with MTX have
been associated with radiographic progression [19]. The
pre-treatment levels of cytokines may also be predictive
of response to biologic DMARDs. Patients with elevated
serum TNF levels may require higher doses of inflixi-
mab, while high levels of IL-17 are possibly predictive of
a subgroup of RA patients resistant to TNF blockade
[20]. Cytokine ratios may also have prognostic signifi-
cance, with the IL-6/IL-10 ratio being associated with
new coronary events in the general population [21].
The “shared epitope” (SE) is a well-recognized genetic
risk factor for, and poor prognostic marker in RA, being
associated with both ACPA positivity and a poorer
response to MTX monotherapy [11, 22–25]. Patients
who do not carry the risk alleles generally have milder
disease, less radiographic progression and are more
likely to respond to DMARDs.
Most studies focused on genotype and profiling of
circulating immune biomarkers in prediction of risk and
response to therapy in patients with RA have been
undertaken in developed world countries. However, RA
in the developing world, where there is often little-or-noaccess to expensive biologic therapies, is associated with
as much, if not more, morbidity, than in developed
countries, underscoring the importance of discerning
clinical utility of traditional DMARD-based therapy in
limited resource settings. To our knowledge, measure-
ment of the SE/risk allele status and its association with
longitudinal alterations in clinical disease activity, as well
as the concentrations of circulating biomarkers of im-
mune activation, specifically autoantibodies, acute phase
reactants and cytokines/chemokines following initiation
of DMARD-based therapy has not been described in
black African patients with early RA.
Accordingly, the objectives of the present study were
to: i) characterize changes in ACPA and cytokines in
relation to disease activity following synthetic DMARD
therapy in an early RA cohort of predominantly black
South African patients; and ii) evaluate changes in
disease activity, APCA and cytokines in relation to geno-
type in the different treatment responder groups.
Methods
After obtaining approval from the Research Ethics Com-
mittees of the Faculties of Health Sciences of the Univer-
sity of Pretoria and the University of the Witwatersrand
140 South African patients who met the 1987 revised
classification criteria for RA and were DMARD-naïve,
attending two public sector rheumatology clinics, were
enrolled as part of the prospective observational Gauteng
Rheumatoid Early Arthritis (GREAT) study [26, 27]. In-
formed written consent was obtained from all participants
before recruitment into the study. Patients were followed
as per routine standard of care, with the attending clini-
cians deciding on the type of DMARD therapy and fre-
quency of follow-up visits. In all, 43 patients were treated
with MTX monotherapy, 33 with MTX in combination
with prednisone; 9 on a combination of MTX and chloro-
quine (CQ), 1 on sulfasalazine (SZP), 1 on CQ monother-
apy, while the remainder were on varying combinations of
all 3 DMARDs without or with prednisone. The initial
dose of MTX was 7.5-15 mg/week [mean (SD) dose 13.1
(3.2) mg/week], gradually increasing to a maximum of
25 mg/week. In 77(55 %) patients low-dose prednisone,
5–7.5 mg daily, was co-prescribed.
Data collected at baseline and 6 months included the
simple disease activity index (SDAI) [28], rheumatoid
factor (RF), ACPA and a panel of cytokines, chemokines
and growth factors.
Assessment of clinical disease activity
The SDAI was used as the measure of disease activity as
this is a validated measure often used in routine clinical
practice.
Subgroup analysis included assessment of SDAI categor-
ies and SDAI responder groups at 6 months. The levels of
Table 1 Demographics of patients (n = 140)
n or median % or IQR
Black ethnicity (%) 124.0 88.5
Females (%) 110.0 79.2
Age in years, median (IQR) 47.8 14.4
Symptom duration in months, median (IQR) 9.7 11.4
Smoking history (%) 34.0 24.2
Nodulosis (%) 27.0 19.3
Rheumatoid factor positive (%) IU/ml 114.0 81.4
ACPA [n at baseline = 126] (%) U/ml 106.0 84.1
Shared Epitope positive [n at baseline =115] (%) 106.0 92.1
CRP baseline,median (IQR) μg/ml 17.1 42.3
SDAI baseline, median (IQR) 41.4 24.1
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(low-disease activity, LDA); ii) SDAI ≤ 26 (moderate-
disease activity, MDA); and iii) SDAI > 26 (high-disease
activity, HDA). SDAI response was categorized accord-
ing to percentage improvement from baseline SDAI
with <50 % being no response, ≥ 50 < 70 % a minor
response, ≥70 < 85 % a moderate response and ≥85 % a
major response [28].
Laboratory investigations
ACPA were measured by immunofluorimetry using the
Immunocap 250 system based on second generation CCP
as antigen and reagents and controls provided by the
manufacturer (Phadia AB, Uppsala, Sweden). According to
the manufacturer the intra-run and inter-run coefficients
of variation (CVs) are 5.1-10.5 % and 2.6-7.7 % respectively,
with values of >10 U/ml deemed positive [26, 27].
C-reactive protein (CRP) and rheumatoid factor (RF,
composite IgM, IgG, IgA) were assayed by immunonephe-
lometry (Siemens Health Care Diagnostics, BN Prospec
Nephelometer, Newark, USA) using reagents and controls
supplied by the manufacturer with results considered posi-
tive when they exceeded values of 5 μg/ml and 11 IU/ml
respectively [26, 27].
Cytokines/chemokines
Circulating cytokines and their antagonists, representative
of various types of immune, inflammatory and structural
cells, were assayed using Bio-Plex suspension multiplex
suspension bead array technology Bio-Rad Laboratories
Inc., Hercules CA, USA) using standards and controls
supplied by the manufacturer for setting up an 8 point
standard curve as reference, as well as validating the assay
with a low and high control serum for each of the 17
analytes. [26, 27]. Intra-run variability was monitored by
introducing 5 previously measured samples with a CV
of <5 % achieved. Inclusion of a blank bead suspension
was used to control for non-specific binding. Results are
expressed as picograms (pg)/ml. Cytokines/chemokines
analysed included IL-1β, IL-1Ra, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, IFN-γ,
TNF, VEGF, CCL2 and CCL4. Ratios of IL-1/IL-1Ra,
IL 17/IL 10, IFN- γ/IL- 4, IL-8/IL-10 and IL-6/IL-10 were
also calculated, albeit in smaller groups of patients.
Genotyping
Genotyping of HLA-DRB1 alleles was performed using a
DNA-based high-resolution typing method, LABType®HD
DRB1 (One Lambda Inc, Canoga Park, California, USA),
utilizing reverse sequence specific oligonucleotide (rSSO)
Luminex xMAP® technology probes; SE classification done
according to the Du Montcel classification [29], with the
groups pooled according to SE status into risk-allele-
positive (S2,S3P) and -negative (S1,S3D,X) subgroups [30].Statistical analysis
The demographic, clinical and biomarker data are de-
scribed using frequencies and percentages for categorical
types such as gender. Medians and ranges were used to
describe the skewed numerical clinical and biomarker
data. The Mann–Whitney test was used to assess differ-
ences in medians for two independent groups, while the
Wilcoxon signed-rank test was used to compare two
dependent groups (i.e., baseline vs. six months). The
Kruskal-Wallis test was used to determine differences in
medians of more than three independent groups. A
p-value of less than 0.05 was deemed significant, and,
where appropriate, Bonferroni corrections to the p-values
for multiple tests were applied. Spearman’s pairwise corre-
lations were used to find the strengths of association
between circulating cytokines and reduction of SDAI at
6 months. Multivariable analyses were performed using
backward stepwise logistic regression on the outcome of
disease activity at 6 months and any baseline clinical and
laboratory variables with a p-value ≤ 0.1 in the univariate
analysis were included in the models.
Results
Patient demographics
The baseline demographic, clinical features and laboratory
indices of disease activity, with the exception of cytokines/
chemokines, for the entire cohort are shown in Table 1
and Additional file 1: Table S1.
Changes in SDAI and biomarker concentrations after
6 months of therapy
These results for SDAI and those biomarkers which de-
creased significantly in concentration following DMARD
therapy are shown in Table 2 (data of all biomarker
changes post-therapy shown in Additional file 1: Table S2).
The median SDAI declined from 41.4 (IQR 24.1) at
baseline to 16 (IQR 15.8) (p = 0.0010. The categories of re-
sponse were: i) no response: n = 58 (41.4 %); ii) minor
Table 2 Significant changes in SDAI scores and circulating
biomarker concentrations following 6 months DMARD therapy
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 140 41.39 24.10 16 .00 15.81 0.0001
CRP (μg/ml) 140 17.10 42.25 8.90 17.35 0.0001
ACPA (IU/ml) 100 516.60 1027.75 255.65 677.20 0.0001
IL-4 (pg/ml) 32 4.70 10.28 1.51 6.53 0.0075
IL-7 (pg/ml) 123 20.32 82.22 16.69 23.46 0.0013
IL-8 (pg/ml) 123 8.79 12.65 5.70 7.09 0.0001
G-CSF (pg/ml) 123 13.82 60.02 7.23 51.61 0.0083
VEGF (pg/ml) 123 168.56 441.33 92.62 167.21 0.0010
Ratio IL-1 / IL-1Ra 37 0.05 0.05 0.03 0.06 0.0130
Ratio IL-17 / IL-10 30 10.42 15.61 3.72 3.81 0.0001
Only those biomarkers which decreased significantly post-therapy are shown
Table 3 Subgroup analysis of changes in SDAI values and
circulating biomarkers following 6 months DMARD, for the
methotrexate (MTX) monotherapy and methotrexate- prednisone
combination therapy groups
Variable n Baseline 6 months P value
MTX only Median IQR Median IQR
SDAI 43 33.58 24.75 16.03 11.05 0.0001
CRP (μg/ml) 43 9.90 21.30 6.90 13.40 0.0048
ACPA (IU/ml) 36 501.60 844.50 310.90 559.60 0.0033
IL-7 (pg/ml) 42 14.78 64.04 14.17 19.73 NS
IL-8 (pg/ml) 42 7.68 8.84 5.01 5.32 0.0091
IL-10 (pg/ml) 7 6.68 48.16 8.41 23.41 NS
VEGF (pg/ml) 42 114.16 240.82 97.52 184.54 NS
Variable n Baseline 6 months P value
MTX PRED Median IQR Median IQR
SDAI 33 38.90 20.64 18.00 18.73 0.0001
CRP (μg/ml) 33 35.90 36.50 11.60 19.10 0.0005
ACPA (IU/ml) 29 598.90 1036.60 367.20 699.50 0.0001
IL-7 (pg/ml) 28 46.67 161.13 21.46 31.06 0.0026
IL-8 (pg/ml) 28 10.35 13.27 5.84 4.03 0.0002
IL-10 (pg/ml) 14 12.99 18.55 8.50 23.95 0.048
VEGF (pg/ml) 28 318.91 482.44 77.08 159.38 0.0044
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(15.7 %); and iv) major response: n = 20 (14.1 %)
(Additional file 1: Table S3). These changes coincided with
significant decreases in the median serum concentrations
of ACPA and several cytokines (IL-4, IL-7, IL-8, G-CSF,
VEGF), as well as the ratios of IL-1β/IL-1Ra and IL-17/IL-
10 (p < 0.05). Although significantly decreased in the entire
cohort, the levels of circulating IL-7, IL-8, G-CSF and
VEGF remained unchanged or increased at 6 months in
41.4 %, 30.1 %, 43.9 % and 42.2 % of patients respectively.
However, the magnitudes of the decrements in the concen-
trations of these biomarkers did not correlate significantly
with the improvement in SDAI or its individual compo-
nents of tender and swollen joint counts (SJC), C-reactive
protein (CRP), physician and patient global assessments.
ACPA levels decreased in the majority of seropositive
cases, 66 (85.7 %), and in a small minority ACPA levels
actually increased, 11 (14.2 %), while seroconversion and
seroreversion were noted in 3 and 8 patients, respect-
ively, following 6 months of therapy. The fall in ACPA
levels was greatest in patients with higher baseline values
(data not shown). There were no associations between
alterations in ACPA post-therapy with either the base-
line SDAI or SDAI at 6 months. In the case of smokers,
there were no differences in the levels of ACPA at base-
line or the magnitudes of the decrements thereof after
6 months between patients with a positive or negative
history of ever having smoked.
Comparison of pre- and post-therapy alterations in SDAI
values and biomarker levels in patients treated with
methotrexate (MTX) without and with prednisone
Subgroup analysis of significant changes in SDAI scores
and circulating biomarkers, stratified by type of DMARD
therapy (MTX monotherapy vs. the combination of
MTX and prednisone) at 6 months, are shown in Table 3.Pre-therapy SJC (p = 0.0458), CRP (p = 0.0250) and IL-7
(p = 0.0110) levels were significantly higher in the com-
bined treatment subgroup, while the SDAI, IL-8 and
VEGF values, although higher, did not achieve statistical
significance. In both subgroups the SDAI scores de-
creased significantly at 6 months, as did CRP, ACPA and
IL-8 levels, while IL-7, IL-10 and VEGF concentrations
also decreased significantly post-therapy in the com-
bined treatment group. The median CRP value post-
therapy remained significantly higher in the combined
treatment subgroup relative to the MTX monotherapy
group (SDAI response in the different treatment groups
is shown in Additional file 1: Table S4).
Assessment of statistically significant biomarker
responses to therapy
These results are shown in Table 4. Subgroup stratifica-
tion of data by SDAI categories at 6 months, into LDA,
MDA and HDA, showed that notable decreases in
ACPA levels occurred in all 3 categories. However, stat-
istical significance was evident in only the LDA and
MDA subgroups, possibly due to a smaller number of
patients in the HDA subgroup. With respect to differ-
ences at baseline, the median ACPA value for the LDA
subgroup was significantly higher than that of the HDA
subgroup (p < 0.034). In the case of the cytokines and
chemokines, the most notable decreases at 6 months
were observed in the LDA subgroup, with significant
Table 4 Significant changes in circulating biomarker
concentrations, stratified at 6 months
SDAI category≤ 11
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 43 32.42 24.71 6.40 5.34 0.0001
CRP (μg/ml) 43 9.50 20.80 6.90 8.10 0.0054
ACPA (IU/ml) 30 936.55 1162.70 344.60 671.80 0.0005
IL-4 (pg/ml) 9 7.50 7.30 1.50 4.00 0.0280
IL-7 (pg/ml) 36 22.22 82.20 16.19 16.74 0.0050
IL-8 (pg/ml) 36 8.05 11.48 5.56 6.15 0.0169
IL-10 (pg/ml) 9 13.30 15.25 6.85 5.64 0.0382
G-CSF (pg/ml) 36 21.99 99.56 5.78 55.94 0.0095
VEGF (pg/ml) 36 154.96 442.84 98.62 158.33 0.0036
SDAI category > 11≤ 26
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 62 42.25 23.39 17.15 6.86 0.0001
CRP (μg/ml) 62 26.50 45.60 8.90 17.00 0.0001
ACPA (IU/ml) 42 483.35 1025.50 252.15 564.70 0.0001
IL-4 (pg/ml) 14 4.08 13.73 2.53 8.47 NS
IL-7 (pg/ml) 55 19.18 61.68 18.17 26.61 NS
IL-8 (pg/ml) 55 8.94 8.92 5.85 6.99 0.0029
IL-10 (pg/ml) 14 14.07 39.13 19.18 19.91 NS
G-CSF (pg/ml) 55 9.45 42.11 7.23 51.61 NS
VEGF (pg/ml) 55 168.10 420.05 84.30 169.40 0.0102
SDAI Category >26
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 35 43.00 28.50 36.21 11.91 NS
CRP (μg/ml) 35 13.00 44.30 17.00 24.40 NS
ACPA (IU/ml) 28 353.60 917.00 177.00 714.40 NS
IL-4 (pg/ml) 9 1.24 7.18 0.62 1.0 NS
IL-7 (pg/ml) 32 46.67 113.17 13.66 32.18 0.0301
IL-8 (pg/ml) 32 8.55 27.69 6.37 14.49 NS
IL-10 (pg/ml) 9 5.76 8.93 5.81 2.97 NS
G-CSF (pg/ml) 32 11.7 39.12 9.87 54.15 NS
VEGF (pg/ml) 32 170.78 484.05 126.02 187.48 NS
Table 5 Changes in SDAI scores and circulating biomarkers,
stratified by shared epitope (risk allele) status
Risk allele negative
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 47 39.18 23.50 18.00 19.50 0.0001
CRP (μg/ml) 47 18.00 43.60 7.00 14.60 0.0002
ACPA (IU/ml) 40 331.90 1006.60 185.60 654.15 0.0032
IL-4 (pg/ml) 10 2.55 7.99 5.24 7.18 NS
IL-8 (pg/ml) 44 7.68 14.15 5.23 5.98 NS
IL-10 (pg/ml) 10 7.34 27.79 19.18 19.91 NS
G-CSF (pg/ml) 44 14.42 36.94 12.18 81.23 NS
VEGF (pg/ml) 44 130.52 512.22 92.22 148.07 NS
Risk allele positive
Variable n Baseline 6 months P value
Median IQR Median IQR
SDAI 68 40.04 22.12 16.00 16.52 0.0001
CRP (μg/ml) 68 17.50 38.70 10.10 17.50 0.0005
ACPA (IU/ml) 56 561.10 911.05 277.60 677.80 0.0001
IL-4 (pg/ml) 19 5.00 9.80 1.00 1.50 0.0007
IL-8 (pg/ml) 65 9.49 12.15 5.97 6.20 0.0001
IL-10 (pg/ml) 19 11.24 18.78 5.53 6.52 0.0440
G-CSF (pg/ml) 65 8.66 42.11 1.85 24.74 0.0442
VEGF (pg/ml) 65 190.43 401.81 95.76 160.99 0.0056
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tions, all of which remained elevated in the HDA sub-
group, with the exception of IL-7. No statistical
difference could be shown in steroid use between the 3
SDAI categories at 6 months. Patients in the LDA sub-
group had a statistically significantly lower SDAI at
baseline than the corresponding value for the MDA
and HDA subgroups combined (p = 0.0070).Associations of genotype with SDAI and circulating
biomarker status pre- and post-therapy
These results are shown in Table 5. Analysis of patients
stratified by risk allele status revealed a significantly higher
(p = 0.0452) pre-therapy circulating APCA level in the risk
allele-positive group, with no differences between those of
the other measured biomarkers, as well as SDAI in the
low- and high-risk allele subgroups. Following therapy,
SDAI scores and CRP and ACPA concentrations de-
creased significantly in both the risk allele-negative
and -positive subgroups. Falls in the concentrations of
circulating cytokines IL-4, IL-8, IL-10, G-CSF and
VEGF (p = 0.0442 – 0.0001) were noted only in the
high-risk allele subgroup, however more patients were
on steroids in this subgroup (p = 0.0368). (SDAI re-
sponse in the different risk allele groups is shown in
Additional file 1: Table S5).
On multivariate analysis the changes in the post-
therapy concentrations of ACPA, IL-7 and G-CSF
(p < 0.05), may have been influenced by the presence of
rheumatoid nodules. However, none of the baseline
biomarkers evaluated was shown to be predictive of
disease activity at 6 months.
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Successful therapy with biologic agents in early and
established RA has been associated with decreases in cir-
culating ACPA and pro-inflammatory cytokine levels
though not always correlating with clinical indices of
disease activity [2–13]. However, very few studies have
addressed this issue in the therapeutic setting of
synthetic DMARDs in early RA, a situation which is
likely to be most important in resource-limited settings,
including sub-Saharan Africa.
In the present study, ACPA levels decreased significantly
post-therapy in the overall cohort of RA patients, as well
as in the various sub-groups categorized according to type
of therapy (MTX monotherapy or MTX in combination
with prednisone), magnitude of post-therapy SDAI cat-
egory, or risk allele status. The exception was the HDA
subgroup in which changes in ACPA and CRP did not
achieve statistical significance, possibly due to sustained
high disease activity, or a smaller number of patients in
the case of ACPA. These findings are in agreement with
an earlier study of 66 RA patients which reported de-
creases in circulating ACPA in a subgroup of early RA pa-
tients treated with various synthetic DMARDs, but which
did not correlate with either treatment response or type of
therapeutic agent [9]. In a more recent study, the absence
of a correlation between alterations in ACPA and clinical
response following treatment with MTX was also noted in
a group of early arthritis patients, although in contrast to
the present study, baseline levels of ACPA were found to
be predictive of response to MTX [12]. However, the ob-
servation in the current study that the median pre-therapy
ACPA value was highest in the subgroup of patients that
achieved LDA, appears to underscore the lack of a clear
relationship between ACPA levels and response to
therapy.
ACPA seroreversion following therapy occurred in
only a few patients (n = 8) as reported by others [31],
while a total of 3 patients seroconverted. Although
ACPA levels decreased in the majority of patients, an in-
crease was observed in others (n = 11, 14.2 %). Although
not shown, no differences in SDAI responses were noted
between those patients with either increased or de-
creased levels of ACPA post-DMARD therapy.
Pooled analysis of risk allele-positive (S2/S3P) and
-negative (S1/S3D/X) patients revealed a significantly
lower baseline ACPA titre in the latter group. Previous
studies have described higher circulating concentrations
of ACPA in RA patients positive for HLA-DRB*0104
relative to those in patients positive for HLA-DRB*0103,
while the S2 and S3P risk alleles have also been reported
to be associated with increased levels of ACPA [32–34].
The association between smoking and predisposition
for development of seropositive RA is well recognized
[35]. However, baseline ACPA levels, as well as themagnitudes of the post-therapy decrements thereof, did
not differ significantly between smokers and non-smokers
in the present study.
Taken together, the aforementioned findings clearly
document significant decreases in circulating ACPA con-
centrations following 6 months of therapy with synthetic
DMARDs, mostly MTX, without or with prednisone, irre-
spective of baseline SDAI, SE or smoking status. However,
the lack of a compelling correlation with changes in clin-
ical indices of disease activity appears to exclude the utility
of serial measurement of ACPA as a strategy to monitor
the efficacy of therapy with these agents over the initial
6 month period. In contrast, other studies based on
therapy with biologic DMARDs such as adalimumab,
rituximab and infliximab reported that measurement of
ACPA has the potential to guide therapy with these agents
[36–39]. Importantly, and not addressed in the present
study, ACPA status, as well as alterations in ACPA during
the course of RA, may have prognostic value as these have
been associated with both disease severity and radiographic
progression [40–49]. Moreover, ACPA levels have also
been found to correlate with diastolic dysfunction and
reduced myocardial mass in patients with RA [50, 51].
With respect to circulating cytokines/chemokines,
these generally declined significantly in the entire cohort
of patients, as did the IL-1β/IL-1Ra and IL-17/IL-10 ra-
tios. However, as reported by others, alterations in these
parameters were not significantly correlated with im-
provements in clinical indices of disease activity follow-
ing treatment of RA patients for 6 months with the
combination of MTX and prednisone [52]. Increases in
the levels of IL-8 following treatment with MTX, which
were noted in 30 % of patients in the present study, have
been shown to be associated with accelerated radio-
graphic progression [53].
With respect to subgroup analyses, comparison be-
tween the MTX monotherapy and MTX + prednisone
subgroups revealed significant decreases in IL-7, IL-8,
IL-10, and VEGF in the latter subgroup post-therapy,
but only IL-8 in the former, possibly supporting the role
of low-dose corticosteroids in the management of early
RA. Interestingly, pre-therapy IL-7 and CRP levels,
which were unknown to the attending clinicians, were
significantly higher in those patients earmarked to
receive combined therapy, possibly consistent with a
perception of more severe disease, perhaps influenced by
the increased SJC noted in the patients who received
MTX and prednisone.
In the various subgroups categorized according to the
magnitude of the SDAI at 6 months, the concentrations
of IL 4, IL-7, IL-8, IL-10, G-CSF and VEGF decreased
significantly in the LDA subgroup post-therapy , while
IL-8 and VEGF, but only IL-7, declined in the MDA and
HDA subgroups, respectively. Persistently elevated levels
Ally et al. BMC Musculoskeletal Disorders  (2015) 16:130 Page 7 of 9of IL-8, G-CSF and VEGF in the HDA subgroup may
implicate neutrophilic inflammation in the immuno-
pathogenesis of more severe disease. However, the lack
of correlation between circulating concentrations of the
individual cytokines with therapy-associated alterations
in disease activity appears to exclude both baseline and
serial measurement thereof as a strategy to monitor the
success of treatment with synthetic DMARDs. As with
ACPA, this contention contrasts with the apparent
utility of baseline measurement of cytokines such as
IL-6, IL-8, CCL2 and/or TNF as predictors of response
to biologic DMARDs, including golimumab, etanercept
and infliximab [16, 54–58].
Differences between cytokine profiles in the risk allele-
negative and –positive subgroups were also detected
post-therapy, possibly reflecting different inflammatory
mechanisms and responses to therapy, although signifi-
cantly more patients were on steroids in the risk allele
subgroup. Nonetheless, neither genotype nor any of the
circulating biomarkers were found to be predictive of
response to therapy.
Potential limitations of the study include firstly, the
fairly small numbers of patients in some of the sub-
groups, especially the HDA subgroup, while the pres-
ence of nodulosis and lack of treatment randomization
may have influenced the analyses. Secondly, 6 months
might be too short a period in which to detect associa-
tions of circulating biomarkers of disease activity with
clinical responses to therapy. In defence of this strategy
however, it has recently been reported that patients who
manifest a poor response to traditional DMARDs follow-
ing 6 months of therapy are unlikely to show further
improvement after 12 months [27].
On the other hand, the strengths of the study include:
i) the demonstration of the apparent limitations of the
measured circulating biomarkers in predicting responses
to therapy with synthetic DMARDs in RA patients with
relatively early disease; ii) HDA post-therapy is associ-
ated with persistently elevated levels of VEGF, IL-8 and
G-CSF; iii) combining MTX with oral corticosteroids
appears to be associated with a more robust decline in
cytokine levels; and iv) ACPA levels measured pre-
therapy are significantly higher in patients with the risk
allele genotype.
Conclusions
Our findings show that synthetic DMARD therapy for
6 months is associated with a significant decrease in
ACPA and pro-inflammatory cytokines, in tandem with
therapeutic response. However, the lack of correlation
with measures of disease activity precludes serial meas-
urement of these biomarkers as a strategy to monitor
early responses to therapy with synthetic DMARDs.
However, the long-term prognostic value of thesebiomarkers, especially in relation to radiographic progres-
sion and functional disability, remains to be established, as
does their potential to guide future cost-effective therap-
ies, of particular importance in resource-limited settings.
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